Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A).

BMJ Open 2013 16;3(7). Epub 2013 Jul 16.

Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.

Objective: Current studies of newborn screening for Fabry disease in Taiwan have revealed a remarkably high prevalence of cardiac-type Fabry disease with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A).

Design: Retrospective cohort study.

Setting: Tertiary medical centre.

Participants: 21 patients with cardiac-type Fabry disease (15 men and 6 women) as well as 15 patients with classic Fabry disease (4 men and 11 women) treated with biweekly intravenous infusions of agalsidase β (1 mg/kg) or agalsidase α (0.2 mg/kg) for at least 6 months.

Outcome Measures: These data were collected at the time before enzyme replacement therapy (ERT) began and followed up after ERT for at least 6 months, including patient demographics, medical history, parameter changes of cardiac status and renal functions, plasma globotriaosylsphingosine (lyso-Gb3) and Mainz Severity Score Index.

Results: After 6-39 months of ERT, plasma lyso-Gb3 was found to be reduced in 89% (17/19) and 93% (14/15) of patients with cardiac-type and classic Fabry disease, respectively, which indicated an improvement of disease severity. For patients with cardiac-type Fabry disease, echocardiography revealed the reduction or stabilisation of left ventricular mass index (LVMI), the thicknesses of intraventricular septum (IVS) and left posterior wall (LPW) in 83% (15/18), 83% (15/18) and 67% (12/18) of patients, respectively, as well as 77% (10/13), 73% (11/15) and 60% (9/15) for those with classic type. Most patients showed stable renal function after ERT. There were statistically significant improvements (p<0.05) between the data at baseline and those after ERT for values of plasma lyso-Gb3, LVMI, IVS, LPW and Mainz Severity Score Index. No severe clinical events were reported during the treatment.

Conclusions: ERT is beneficial and appears to be safe for Taiwanese patients with cardiac-type Fabry disease, as well as for those with the classic type.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2013-003146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717460PMC
July 2013
30 Reads

Publication Analysis

Top Keywords

fabry disease
24
cardiac-type fabry
16
patients cardiac-type
12
fabry
9
men women
8
fabry mutation
8
agalsidase mg/kg
8
enzyme replacement
8
83% 15/18
8
disease men
8
replacement therapy
8
hotspot late-onset
8
classic fabry
8
chinese hotspot
8
late-onset fabry
8
patients
7
disease
7
cardiac-type
5
months ert
4
severity score
4

Similar Publications